Quarterly Period Covered: This 10-Q filing covers STERIS plc's first quarter of fiscal year 2027, ending June 30, 2026 (period from April 1, 2026 to June 30, 2026) Company Information: STERIS plc is incorporated in Ireland (Dublin) and operates in the orthopedic, prosthetic, and surgical appliances and supplies industry (SIC code 3842), with a fiscal year ending March 31 Financial Data Structure:…

Our analysis rates this filing NEUTRAL. STERIS plc presents a balanced risk profile appropriate for a moderate concern assessment. The primary concern is the ongoing multi-year restructuring program spanning through June 2026, which will continue to generate severance and rationalization costs…

Concern level: ELEVATED (5.2/10). Key factors: Fiscal 2024-2025 restructuring program ongoing through June 2026 with employee severance and product rationalization costs creating near-term operational headwinds; Management tone neutral with cautious undertones, suggesting measured outlook rather than confidence; Restructuring program represents sustained transformation effort with multi-year…

Notable risk changes: Restructuring program remains active with employee severance and product rationalization components continuing through fiscal 2026, indicating sustained operational transformation efforts; Illinois environmental litigation has been settled, removing ongoing legal exposure in that jurisdiction; IEEPA tariff refund disclosed as contingent gain opportunity, though timing and realization remain…

No earnings surprise data found in provided excerpt.

The model predicts STE will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.